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Summary
Conducting clinical studies in the paediatric population is
complex and difficult. Paediatricians deal with a vulnerable
population, which primarily needs protection and where
patient numbers are always low. In addition, the pharma-
ceutical industry often demonstrates lack of interest due to
the small and non-rewarding market. Public awareness for
the need of paediatric research is likewise limited. This res-
ults in lack of funding for academic studies. In Switzer-
land, there is a new initiative that strives to overcome the
given barriers and hurdles. SwissPedNet is still in a start-
up phase, but it is now ready for all collaborations of in-
terest and keen to work together with all stakeholders on
the medical progress and improvement of paediatric clinic-
al research with the overall goal of implementing evidence-
based medicine for our children (www.swisspednet.ch).
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Introduction
Progress in medical care is tightly linked to the translation
of novel findings to the management of patients. Research
in paediatrics and research dedicated to children is funda-
mental for progress in medicine, not at least since many
diseases and chronic traits first manifest themselves during
childhood.
It is particularly true in paediatrics that rare diseases, con-
genital or acquired, often permit exceptional insights into
pathophysiological mechanisms that also apply to adult
patients. In addition, physicians for adults benefit from
what has been learned in the sick child. Many chronic dis-
eases originate in early childhood, and long-term observa-
tions and longitudinal paediatric cohort studies contribute
greatly to the understanding of disease evolvement. Fur-
thermore, there is increasing evidence that early infancy is
a vulnerable developmental phase when many biological
systems are still developing and organs finalise their devel-
opment. The "Barker Hypothesis" states that during these
early phases of life many environmental factors modify and
program normal and abnormal organ development, respect-
ively. A better understanding of the processes involved in
this early organ development provides unique opportunities
for early disease recognition using novel biomarkers and,
subsequently, early preventative and therapeutic strategies.
The latter are the basics for the emerging field of personal-
ised medicine in paediatrics.
It is also particularly true that research in paediatrics is
still a neglected discipline. The barriers to proper research
on e.g. child drug development include several complex
factors, such as lack of a suitable infrastructure and com-
petence for conducting paediatric clinical trials, difficulties
in trial design, ethical worries and many others [1].
The challenges and demands to conducting clinical trials
in children have been faced by paediatricians of the five
Swiss university children’s hospitals (Basel, Bern, Geneva,
Lausanne, and Zurich) as well as the three other class
A children’s hospitals (Aarau, Lucerne and St. Gallen) in
Switzerland: Together they have joined their efforts and
created SwissPedNet, the Swiss research network of clinic-
al paediatric hubs in 2012. The SwissPedNet collaborates
with existing paediatric research groups such as the Swiss
Paediatric Oncology Group (SPOG) and the Swiss Neonat-
al Network & Follow-up Group (Swiss Neonet).
The emergence of paediatric research
networks and their (non) funding
Paediatric research networks are emerging all over the
world. The German Paediatric Network (PAED-Net) was
established in 2002 with a public grant from the German
Ministry of Education and Research. Six university med-
ical centres, staffed with one MD and one study nurse
each, and a coordination office built the core of PAED-Net,
collaboration with other university hospitals, non-academ-
ic hospitals and private physicians ensured patient recruit-
ment in clinical trials [2]. Securing funding for the pae-
diatric network by the state in England has proven highly
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successful, as it has allowed numerous important clinical
research projects beneficial for children to be started.
Moreover, securing funding has guaranteed continuation of
these research projects at a high quality level. This in turn
has made England an attractive partner for paediatric clin-
ical research.
Subsequently, when the Paediatric Regulation came into
force in 2007, many European networks emerged. MCRN,
Medicine for Children Research Networks, perform very
successfully in the UK and the Netherlands. The National
Institute for Health Research NIHR MCRN is funded by
the Department of Health and works in partnership with the
NIHR Clinical Research Network (NIHR CRN) to improve
the UK’s clinical research environment and maximize the
development of safe and effective medicines and formula-
tions for children [3].
Funding or respectively non-funding remains a major issue
for the endeavours of paediatric research networks. At the
5th Enpr-EMA workshop in June 2013 it was proposed that
Enpr-EMA should elaborate a “business model case” for
core funding, to provide estimate on overall costs, staff re-
sources, etc. This would help networks as a basis for nego-
tiations with potential funding sources [4].
Limited commercial interest and
collaboration with pharmaceutical
industry
From the perspective of paediatricians, there is a large gap
in the availability of thoroughly studied and licensed dia-
gnostic or therapeutic means for children as compared to
adults. Results from studies in adults can rarely and, if at
all, only barely be transposed to neonates, toddlers, chil-
dren or adolescents because of the remarkable biological
differences. With the adoption of the European Paediatric
Regulation in January 2007, involvement of commercial
interests is mandatory and has lead to the obligation to
provide paediatric investigational plans (PIP) for all new
drugs. Nevertheless, five years after adoption of the paedi-
atric regulation no increase of paediatric trials in EU coun-
tries could be observed [5].
During its first six years in operation, FINPEDMED, the
Finnish Investigators Network for Paediatric Medicines,
received 91 trial requests, 18 trials were started, and in 24
cases, sponsors did not select Finnish investigators. This
experience from Finland highlights the need for Nordic
collaboration to increase expertise, recruitment base and at-
tractiveness for sponsors [6].
It is not realistic for a paediatric research network to be-
come self-supporting by conducting commercial paediatric
studies.
Lack of suitable infrastructure and
competence for conducting paediatric
clinical trials
The initiators of SwissPedNet are convinced that paediatric
clinical research needs a national platform to be successful
and internationally competitive. The paediatric population
ranging from premature babies to adolescents can neither
be treated nor investigated within the adult medicine set-
tings, which lack specialized personnel and infrastructure.
Moreover, it is globally recognised that the paediatric pop-
ulation is a population with special legal and ethical needs.
Indeed, the Paediatric Regulation came into force in the
European Union in 2007. There is a specific ICH Guideline
for clinical investigation of medicinal products in the pae-
diatric population, and within national law, Art. 21 to 24 of
the Swiss law on human research demand special require-
ments for research in children and adolescents. The fulfil-
ment of these requirements has not yet been established
in Switzerland. Thus, to comply with above regulations, a
paediatric-specific platform matching the research efforts
in adult medicine is important.
In view of the many methodological challenges and tech-
nical requirements associated with modern clinical trials,
these are best and most efficiently conducted within the
framework of clinical trial units (CTUs). In 2007, the Swiss
National Science Foundation (SNSF) funded the establish-
ment of six academic clinical trial units (CTUs) in Switzer-
land. As of May 2011, the six CTUs are operational at
the University Hospitals of Basel, Bern, Geneva, Lausanne,
Zurich and the Kantonsspital St. Gallen. Academic clinical
research in Switzerland is profiting significantly from this
infrastructure. While these CTUs advise and support pae-
diatric clinical trials, none of them is particularly special-
ised in conducting clinical trials in children. They do, of
course, provide knowledge and support to the best of their
ability, especially in respect to design, quality, and statistics
and data management. Nevertheless, being academic clin-
ical research organisations, none of the CTUs has dedicated
facilities suitable for children from the neonate to the ad-
olescent, nor are they staffed with the paediatricians or pae-
diatric nurses able to address these special needs.
International collaboration of
SwissPedNet
SwissPedNet is tightly linked via Enpr-EMA, the European
Network of Paediatric Research at the European Medicines
Agency, to internationally share high quality medical ex-
pertise and robust data from Switzerland.
SwissPedNet is member of Enpr-EMA. This is a network
of research networks and experts and, amongst other activ-
ities, Enpr-EMA facilitates the pharmaceutical industry’s
access to paediatric clinical study centres and experts. They
also include their members in consultations of new
guidelines and lists of development programs for drugs
used in children [7].
Known hurdles in paediatric research are peculiarities in
development of scientific protocols for small sample sizes
and the difficulties in recruitment. For the paediatric spe-
cific standards, SwissPedNet actively searched and agreed
on a collaboration with a second international body: StaR
Child Health. StaR Child Health is an initiative that seeks
to improve the quality of design, conduct, and reporting of
clinical research by promoting the use of modern research
standards [8].
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Conclusion
Networks are essential to cope with the challenges in pae-
diatric research. SwissPedNet fills the gap within Switzer-
land and has already established international collabora-
tions as the paediatric population with their rare diseases is
small. Proper research infrastructure within the children’s
hospitals is crucial for competitive and reliable study con-
duct in and with children. Collaboration with industry can
still be improved. In Switzerland, the initiators of Swis-
sPedNet set the course for the future nationally and inter-
nationally.
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